Bloomberg Law
March 18, 2022, 6:19 PMUpdated: March 18, 2022, 9:19 PM

Warren Bid to Grab Xtandi Cancer Drug Patents Gets Firm Rebuke (1)

Ian Lopez
Ian Lopez
Senior Reporter

An effort by Sen. Elizabeth Warren (D-Mass.), other lawmakers, and advocacy groups to force the government to green-light production of a cancer drug by third-party manufacturers is meeting stiff opposition from nearly 100 interest groups and individuals.

President Joe Biden’s Health and Human Services Department should flat-out reject a plea for the government to grant so-called “march-in rights” for patents on the prostate cancer drug Xtandi, the Bayh-Dole Coalition and other individuals and interest groups said in a letter to HHS Secretary Xavier Becerra. Similar requests for march-in rights were rejected several times during the Obama administration, according to the ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.